v3.24.1.u1
Stockholders’ Equity (Tables)
 3 Months Ended
Mar. 29, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Employee Stock-Based Compensation Expense
We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):
Three Months Ended March 31,
20242023
Research and development$3,892 $3,252 
Selling, general and administrative15,221 13,409 
Total stock-based compensation expense$19,113 $16,661 
Stock-based compensation expense for each type of award under our equity incentive plans and ESPP were as follows (in thousands):
Three Months Ended March 31,
20242023
Stock options$1,738 $2,207 
Restricted stock units15,434 12,607 
Performance stock units727 794 
Employee stock purchase plan
1,214 1,053 
Total stock-based compensation expense$19,113 $16,661 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following weighted-average assumptions to determine the weighted-average grant date fair value of $20.19 per share for the 2024 TSR-based RSUs:
Fair value of Exelixis common stock on grant date
$21.71 
Expected volatility
36.68 %
Risk-free interest rate
4.42 %
Dividend yield
— %